PlGF-1 is a glycoprotein that is primarily expressed in the placenta. It binds to the VEGF receptor-1 (VEGFR-1), also known as Flt-1, and modulates the activity of VEGF-A, another member of the VEGF family. This interaction enhances the angiogenic response, promoting the growth and development of new blood vessels .
Recombinant PlGF-1 is widely used in research to study its role in various physiological and pathological processes. It is particularly valuable in investigating the mechanisms of angiogenesis and the development of potential therapeutic strategies for diseases characterized by abnormal blood vessel growth .
The therapeutic potential of PlGF-1 lies in its ability to promote angiogenesis. This makes it a promising candidate for treating conditions such as ischemic heart disease, peripheral artery disease, and wound healing. Additionally, PlGF-1 has been explored as a potential target for anti-angiogenic therapies in cancer treatment .